A Phase 2b/3, Randomized, Double Blind, Dose Confirming Study of the Safety, Efficacy and Tolerability of Apricitabine Versus Lamivudine in Treatment-Experienced HIV-1 Infected Patients With the M184V/I Mutation in Reverse Transcriptase.

Trial Profile

A Phase 2b/3, Randomized, Double Blind, Dose Confirming Study of the Safety, Efficacy and Tolerability of Apricitabine Versus Lamivudine in Treatment-Experienced HIV-1 Infected Patients With the M184V/I Mutation in Reverse Transcriptase.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Apricitabine (Primary) ; Lamivudine
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 21 Apr 2012 Additional location (Germany) added as reported by European Clinical Trials Database record.
    • 24 Mar 2012 Additional locations (France. United Kingdom and Portugal) added as reported by European Clinical Trials Database record.
    • 24 Mar 2012 This trial has been completed in (Portugal, Italy) and recruiting in (France and United Kingdom) as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top